443TiPFirst-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population. (23rd October 2018) - Gomez-Roca, C A; Garralda-Cabanas, E; Cruzalegui, F; Ausseil, F; Zorza, G; Delfour, O; Besse, J; Akla, B; Gautier, S; Adam, J; Lacroix-Triki, M; Passioukov, A; et al.